Covington Represented uniQure in Sale of Gene Therapy Manufacturing Facility to Genezen

PR Contacts

How Can We Help You?

Covington Represented uniQure in Sale of Gene Therapy Manufacturing Facility to Genezen

July 23, 2024

WASHINGTON—Covington represented uniQure, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, in the sale of its Lexington, Massachusetts manufacturing facility to Genezen, a leading contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus (AAV) technologies.

Genezen acquired uniQure’s commercial-scale gene-therapy manufacturing facility for total consideration of $25 million, comprised of $12.5 million of newly issued Series C Preferred Stock and a $12.5 million convertible note. As a result of the transaction, uniQure becomes a meaningful shareholder of Genezen. In addition, Matt Kapusta, chief executive officer of uniQure, has joined Genezen’s Board of Directors.

The Covington team included Stephen Infante, Jas Johnson, Eric Tang and Winona Paez (M&A), Lily Hines (Tech Transactions), Jessica Milner and Robert Kim (Life Sciences Transactions), Heather Haberl and Zach Schutz (Real Estate), Jenna Wallace and Molly Ramsden (Benefits), Paula Katz, Grant Dixon and Sophie DeBode (Regulatory), Brian Harris (Tax), and Jennifer Uren and Amani Ahmed (Finance).